Linezolid

Tier C — Watch / trade

Linezolid

Pfizer Inc.

Originator

2000

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：50S ribosomal subunit

Brand：Zolodine, Zyvoxam, Zyvoxid, Zyvoxa, Zyvox

Indications (approved)：非复杂性皮肤和皮肤结构感染, Pneumonia, Complicated skin and skin structure infection, Bacteraemia, Bacterial infection, Healthcare-associated pneumonia, Infectious disease, Staphylococcal infection

Regional status

Approved

2000-04-18

Discontinued

2001-12-01

China

Approved

2006-09-12

Japan

Approved

2001-04-04

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Linezolid?

Approved indications include: 非复杂性皮肤和皮肤结构感染, Pneumonia, Complicated skin and skin structure infection, Bacteraemia, Bacterial infection, Healthcare-associated pneumonia, Infectious disease, Staphylococcal infection.

When does the Linezolid patent expire?

No public expiry year is available for Linezolid yet; this page updates once verified.

How do I get a quote for Linezolid intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27